HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01520272|
Recruitment Status : Completed
First Posted : January 27, 2012
Last Update Posted : April 5, 2018
- Cervical cancer is one of the leading causes of cancer death in women worldwide and in Uganda. It is caused by the human papillomavirus (HPV). A vaccine against HPV was offered for all 10-year-old girls in the Nakasongola district of Uganda from October 1, 2008, to October 31, 2009. The HPV vaccine requires three doses; however, some girls received only one or two doses. Researchers want to compare vaccine immunogenicity in girls who received all three doses with those who had only one or two doses.
- To examine the immunogenicity (antibody levels) of girls in Uganda who received only one, two or three doses of HPV vaccine.
- Girls who will be at least 12 years old by October 31, 2011, and had at least one dose of the HPV vaccine.
- All participants will come from the Nakasongola district of Uganda.
- Participants will have a physical exam and answer questions about their medical history and HPV risk.
- Participants will provide a single blood sample for testing.
- Treatment and vaccines will not be provided as part of this study. Girls who did not receive all three doses of the HPV vaccine will be given information about the nearest health center. Health centers will provide the missed doses free of charge.
|Condition or disease|
|HPV16 Anitbody Levels Post Vaccination HPV18 Antibody Levels Post Vaccination|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||376 participants|
|Official Title:||Immunogenicity of Bivalent HPV Vaccine Among Partially Vaccinated Young Adolescent Girls in Uganda|
|Study Start Date :||January 2, 2012|
|Study Completion Date :||June 28, 2017|
- HPV Immunogenicity [ Time Frame: Ongoing ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01520272
|District of Nakasangola|
|Principal Investigator:||Allan Hildesheim, Ph.D.||National Cancer Institute (NCI)|